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Background: Cardiac allograft vasculopathy (CAV) is one of the main limiting factors in long term survival in heart transplant patients. 
Vitamin C and E (vit C & E) are potent antioxidants which may have a role in slowing CAV progression. Fang et al reported previously 
(Lancet. 2002: 359: 1108-1113) that vit C & E with a calcineurin inhibitor can control the progression of CAV through a randomized 
intravascular ultrasound trial. In the current age of tacrolimus (TAC) and mycophenolate mofetil (MMF) it is not clear if vit C & E remain 
beneficial.
methods: Between 2006 and 2011, we evaluated 172 patients who were maintained on TAC/MMF and divided them into those who were 
treated with vit C & E and those who were not. Outcomes including 3-year survival, freedom from CAV, and freedom from non-fatal major 
adverse cardiac events (NF-MACE), defined as myocardial infarction, new congestive heart failure, percutaneous coronary intervention/
angioplasty, ICD/pacemaker implant, stroke, were assessed (see table).
Endpoint Control(n=71) Vitamin C & E (n=101) P-Value
3-Year Survival 78.9% 91.1% 0.023
3-Year Actuarial Freedom from CAV 89.8% 84.0% 0.331
Average Peak ISHLT CAV Grade 1.3±0.5 1.4±0.5 0.198
3-Year Actuarial Freedom from NF-MACE 83.8% 87.9% 0.635
results:  Vit C & E did not appear to protect against CAV at 3 years post-transplantation. The average peak CAV grade was not different 
between the two groups. However, 3-year patient survival was significantly lower in the control group compared to the treatment group.
conclusion:  The use of vit C & E in heart transplant patients on maintenance TAC and MMF does not appear to be helpful in preventing 
CAV but may decrease mortality post-transplant.
